Pecic V, Stankovic-Djordjevic D, Nestorovic M, Radojkovic M, Marjanovic H, Ilic B, Milojkovic M
Clinic for General Surgery, Clinical Center Nis, Nis, Serbia.
J BUON. 2011 Apr-Jun;16(2):277-81.
The aim of this study was to compare patients with hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV) infection with patients with liver cirrhosis associated with HCV virus infection.
Forty-five patients were prospectively analyzed, all with HCV infection. Patients were divided into 2 groups. The first group consisted of 21 patients with histologically proven HCC and the second one consisted of 24 patients with liver cirrhosis without HCC. PCR was carried out in order to diagnose active HCV infection and HCV genotyping.
There was no statistically significant difference in the structure of the compared groups of patients in relation to sex and age. In 76.19% of the patients with HCC cirrhosis preceded HCC, while 23.81% of the patients had chronic hepatitis. The prevalence of genotypes in the HCC group was 1a in 4.76%, 1b in 80.95% and 2a in 14.29%. In the group with liver cirrhosis 1a was detected in 20.83%, 1b in 45.83%, 2a in 12.50%, 2b in 4.17% and 3a in 16.67% of the patients. The prevalence of genotype 1b was significantly higher among HCV RNA positive patients with HCC compared to the group with liver cirrhosis and HCV RNA positive patients (x(2)=4.48; p=0.034). In the group where cirrhosis preceded HCC, genotype 1b was found in 75% of the cases, genotype 2a in 18.75%, and genotype 1a in 6.25%. Genotype 1b was detected in 100% of patients with chronic hepatitis and HCC.
The role of HCV infection in the development of HCC has not been fully clarified. Most authors evaluate the role of individual genotypes in the pathogenesis of HCC. This study has shown that the dominant genotype found in patients with HCC is 1b.
本研究旨在比较丙型肝炎病毒(HCV)感染相关的肝细胞癌(HCC)患者与HCV病毒感染相关的肝硬化患者。
前瞻性分析了45例均为HCV感染的患者。患者分为2组。第一组由21例经组织学证实为HCC的患者组成,第二组由24例无HCC的肝硬化患者组成。进行聚合酶链反应(PCR)以诊断活动性HCV感染和HCV基因分型。
在患者的比较组中,性别和年龄结构无统计学显著差异。在76.19%的HCC患者中,肝硬化先于HCC出现,而23.81%的患者患有慢性肝炎。HCC组中基因型的患病率为1a占4.76%,1b占80.95%,2a占14.29%。在肝硬化组中,20.83%的患者检测到1a,45.83%的患者检测到1b,12.50%的患者检测到2a,4.17%的患者检测到2b,16.67%的患者检测到3a。与肝硬化组和HCV RNA阳性患者相比,HCC患者中HCV RNA阳性患者的1b基因型患病率显著更高(x(2)=4.48;p=0.034)。在肝硬化先于HCC的组中,75%的病例发现1b基因型,18.75%的病例发现2a基因型,6.25%的病例发现1a基因型。在慢性肝炎和HCC患者中,100%检测到1b基因型。
HCV感染在HCC发生发展中的作用尚未完全阐明。大多数作者评估个体基因型在HCC发病机制中的作用。本研究表明,HCC患者中发现的主要基因型是1b。